Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
出版年份 2023 全文链接
标题
Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
作者
关键词
-
出版物
Cancer Management and Research
Volume Volume 15, Issue -, Pages 1233-1243
出版商
Informa UK Limited
发表日期
2023-11-03
DOI
10.2147/cmar.s386799
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Safety of MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
- (2022) Alexis Cortot et al. Clinical Lung Cancer
- Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer
- (2022) Ying Fan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cancer treatment and survivorship statistics, 2022
- (2022) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.
- (2022) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Annual report to the nation on the status of cancer, part 1: National cancer statistics
- (2022) Kathleen A. Cronin et al. CANCER
- Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report
- (2022) Liang-Wei Tseng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MET alterations in non-small cell lung cancer – current perspectives and future challenges
- (2022) Jordi Remon et al. Journal of Thoracic Oncology
- Oncogene alterations in non-small cell lung cancer—have we MET a new target?
- (2022) Wolfram C. M. Dempke et al. Translational Lung Cancer Research
- Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study
- (2022) Jürgen Wolf et al. EUROPEAN JOURNAL OF CANCER
- MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts
- (2021) Kaibin Zhu et al. Aging-US
- 1256P Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial
- (2021) R.S. Heist et al. ANNALS OF ONCOLOGY
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- (2021) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.
- (2021) Juergen Wolf et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
- (2021) Leylah M. Drusbosky et al. Journal of Hematology & Oncology
- MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING
- (2021) Yong Zhang et al. Cancer Discovery
- Roles of MET in human cancer
- (2021) Xin Yang et al. CLINICA CHIMICA ACTA
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I dose‐escalation study of capmatinib ( INC 280) in Japanese patients with advanced solid tumors
- (2019) Taito Esaki et al. CANCER SCIENCE
- Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway
- (2019) Yuyao Shen et al. MOLECULAR AND CELLULAR PROBES
- Capmatinib for the treatment of non-small cell lung cancer
- (2019) Johan Filip Vansteenkiste et al. Expert Review of Anticancer Therapy
- MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC
- (2017) William Sterlacci et al. VIRCHOWS ARCHIV
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
- (2016) J. H. Tong et al. CLINICAL CANCER RESEARCH
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
- (2008) Katsuhiro Okuda et al. CANCER SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started